Krystal Biotech, Inc., a leading gene therapy company, has released its annual 10-K report, showcasing significant financial and operational achievements for the fiscal year. The report highlights the company's robust financial performance, successful commercialization of its FDA-approved product VYJUVEK, and strategic initiatives aimed at expanding its global footprint and advancing its clinical pipeline. Financial Highlights Business Highlights Strategic Initiatives Challenges and Risks SEC Filing: Krystal Biotech, Inc. [ KRYS ] - 10-K - Feb. 19, 2025